![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BATF3 |
Gene summary for BATF3 |
![]() |
Gene information | Species | Human | Gene symbol | BATF3 | Gene ID | 55509 |
Gene name | basic leucine zipper ATF-like transcription factor 3 | |
Gene Alias | JDP1 | |
Cytomap | 1q32.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9NR55 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55509 | BATF3 | PTC04 | Human | Thyroid | PTC | 2.29e-02 | 1.68e-01 | 0.1927 |
55509 | BATF3 | ATC13 | Human | Thyroid | ATC | 8.48e-15 | 3.36e-01 | 0.34 |
55509 | BATF3 | ATC2 | Human | Thyroid | ATC | 1.80e-12 | 9.53e-01 | 0.34 |
55509 | BATF3 | ATC5 | Human | Thyroid | ATC | 1.02e-18 | 3.72e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961520 | Thyroid | PTC | response to virus | 162/5968 | 367/18723 | 4.52e-07 | 7.41e-06 | 162 |
GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
GO:003009933 | Thyroid | ATC | myeloid cell differentiation | 170/6293 | 381/18723 | 4.26e-06 | 4.68e-05 | 170 |
GO:0002573110 | Thyroid | ATC | myeloid leukocyte differentiation | 86/6293 | 208/18723 | 1.15e-02 | 4.11e-02 | 86 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BATF3 | SNV | Missense_Mutation | novel | c.152G>T | p.Arg51Ile | p.R51I | Q9NR55 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BATF3 | SNV | Missense_Mutation | rs764402872 | c.233N>A | p.Arg78Gln | p.R78Q | Q9NR55 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BATF3 | SNV | Missense_Mutation | c.327N>C | p.Met109Ile | p.M109I | Q9NR55 | protein_coding | tolerated(0.16) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
BATF3 | SNV | Missense_Mutation | c.119N>A | p.Arg40Gln | p.R40Q | Q9NR55 | protein_coding | tolerated(0.23) | probably_damaging(0.914) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
BATF3 | SNV | Missense_Mutation | c.157C>T | p.Arg53Trp | p.R53W | Q9NR55 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
BATF3 | SNV | Missense_Mutation | c.119G>A | p.Arg40Gln | p.R40Q | Q9NR55 | protein_coding | tolerated(0.23) | probably_damaging(0.914) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
BATF3 | SNV | Missense_Mutation | novel | c.280N>A | p.Ala94Thr | p.A94T | Q9NR55 | protein_coding | tolerated(0.39) | benign(0.062) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
BATF3 | deletion | Frame_Shift_Del | c.134delN | p.Asn45ThrfsTer40 | p.N45Tfs*40 | Q9NR55 | protein_coding | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
BATF3 | deletion | Frame_Shift_Del | c.134delA | p.Asn45ThrfsTer40 | p.N45Tfs*40 | Q9NR55 | protein_coding | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |||
BATF3 | SNV | Missense_Mutation | c.135N>A | p.Asn45Lys | p.N45K | Q9NR55 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |